Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Retained Earnings (2017 - 2025)

Sutro Biopharma's Retained Earnings history spans 9 years, with the latest figure at -$931.2 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 30.35% year-over-year to -$931.2 million; the TTM value through Sep 2025 reached -$931.2 million, down 30.35%, while the annual FY2024 figure was $39000.0, 100.01% up from the prior year.
  • Retained Earnings for Q3 2025 was -$931.2 million at Sutro Biopharma, down from -$874.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $39000.0 in Q4 2024 and bottomed at -$931.2 million in Q3 2025.
  • The 5-year median for Retained Earnings is -$264.4 million (2021), against an average of -$332.6 million.
  • The largest annual shift saw Retained Earnings surged 100.52% in 2023 before it plummeted 10205814.29% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$333.4 million in 2021, then soared by 99.81% to -$618000.0 in 2022, then plummeted by 90419.09% to -$559.4 million in 2023, then skyrocketed by 100.01% to $39000.0 in 2024, then plummeted by 2387774.36% to -$931.2 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Retained Earnings are -$931.2 million (Q3 2025), -$874.3 million (Q2 2025), and -$862.8 million (Q1 2025).